Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas

High-grade meningiomas are associated with neuro-cognitive morbidity and have limited treatments. High-grade meningiomas harbor an immunosuppressive tumor microenvironment (TME) and programmed death-ligand 1 (PD-L1) expression may contribute to their aggressive phenotype. Here, we present the result...

Descripción completa

Detalles Bibliográficos
Autores principales: Brastianos, Priscilla K., Kim, Albert E., Giobbie-Hurder, Anita, Lee, Eudocia Quant, Wang, Nancy, Eichler, April F., Chukwueke, Ugonma, Forst, Deborah A., Arrillaga-Romany, Isabel C., Dietrich, Jorg, Corbin, Zachary, Moliterno, Jennifer, Baehring, Joachim, White, Michael, Lou, Kevin W., Larson, Juliana, de Sauvage, Magali A., Evancic, Kathryn, Mora, Joana, Nayyar, Naema, Loeffler, Jay, Oh, Kevin, Shih, Helen A., Curry, William T., Cahill, Daniel P., Barker, Fred G., Gerstner, Elizabeth R., Santagata, Sandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921328/
https://www.ncbi.nlm.nih.gov/pubmed/35289329
http://dx.doi.org/10.1038/s41467-022-29052-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921328/
https://www.ncbi.nlm.nih.gov/pubmed/35289329
http://dx.doi.org/10.1038/s41467-022-29052-7

Ejemplares similares